RT Journal Article
SR Electronic
T1 Statistical Analysis Plan for the Blood Pressure Postpartum (BP<sup>2</sup>) study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.25.23289082
DO 10.1101/2023.04.25.23289082
A1 Brew, Bronwyn K
A1 Chambers, Georgina M
A1 Kotevski, Damian
A1 Henry, Amanda
A1 ,
YR 2023
UL http://medrxiv.org/content/early/2023/04/25/2023.04.25.23289082.abstract
AB Background Hypertensive Disorders of Pregnancy (HDP) complicate 5-10% of pregnancies globally: 2-5% preeclampsia, 3% gestational hypertension, and 0.5-2% chronic hypertension. It is epidemiologically well established that adverse health effects of HDP do not end with the pregnancy: these conditions are associated with increased lifetime cardiovascular disease (CVD) risks. However, intervention trial data in the early years postpartum after HDP, focussed on early intervention to reduce women’s ongoing CVD risks after HDP, is sparse.Methods The Blood Pressure Postpartum Trial (BP2) is a 3-arm randomised controlled trial investigating three different methods of follow-up and lifestyle behaviour change in the first 12 months postpartum following a pregnancy affected by HDP. The trial was prospectively registered on the Australian and New Zealand Clinical trials registry (registration: ACTRN12618002004246) and the study protocol has previously been published (Henry A et al, Pregnancy Hypertension 2020; 22: 1-6). This manuscript details the pre-analysis, pre-specified Statistical Analysis Plan.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialACTRN12618002004246Clinical Protocols https://doi.org/10.1016/j.preghy.2020.07.001 Funding StatementThis study was funded by the NSW Health Translational Research Grants Scheme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Human Research Ethics Committee of the South Eastern Sydney Local Health District gave ethical approval for this work (ref 18/193).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.All data produced in the present work are contained in the manuscript.BP2Blood Pressure Postpartum StudyCHChronic hypertensionCH+PEChronic hypertension with superimposed preeclampsiaCRPC-reactive proteinCVDCardiovascular diseaseeGFREstimated glomerular filtration rateGHGestational hypertensionGHSGet Healthy ServiceGPGeneral PractitionerHDPHypertensive disorders of pregnancyHOMAHomeostatic assessment (of insulin resistance)hsCRPHigh-sensitivity C-reactive proteinPEPreeclampsiaPPPostpartumSAPStatistical Analysis PlanSDStandard DeviationUNSWUniversity of New South Wales